(Q30666898)

26 June 2017

1 reference

title

Phase III data on Caelyx in ovarian cancer (English)

1 reference

26 June 2017

1 reference

1

1 reference

26 June 2017

Hamilton A

2

1 reference

26 June 2017

publication date

1 December 2001

1 reference

European Journal of Cancer

26 June 2017

published in

1 reference

26 June 2017

volume

37 Suppl 9

1 reference

26 June 2017

page(s)

S15-8

1 reference

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Hexamethylmelamine in platinum-resistant ovarian cancer: how active?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

Activity of anthracyclines in refractory ovarian cancer: recent experience and review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900330-6

7 January 2021

10.1016/S0959-8049(01)00330-6

Identifiers

DOI

1 reference

26 June 2017

1 reference